Insider Buying: GSK (LON:GSK) Insider Buys 1,266 Shares of Stock

GSK plc (LON:GSK – Get Free Report) insider Vishal Sikka bought 1,266 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average price of GBX 5,069 per share, with a total value of £64,173.54.

GSK Stock Performance

LON GSK traded up GBX 35.50 during trading on Tuesday, hitting GBX 1,960. The company’s stock had a trading volume of 27,888,139 shares, compared to its average volume of 8,764,782. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The firm has a 50 day moving average price of GBX 1,955.63 and a 200 day moving average price of GBX 1,966.35. The firm has a market cap of £78.60 billion, a P/E ratio of 13.79, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29. GSK plc has a 52 week low of GBX 1,288.61 and a 52 week high of GBX 2,282.

Get GSK alerts:

GSK (LON:GSK – Get Free Report) last posted its quarterly earnings data on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. The company had revenue of GBX 762.90 billion during the quarter. GSK had a return on equity of 35.78% and a net margin of 17.78%. Equities research analysts forecast that GSK plc will post 175.980975 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on GSK shares. Jefferies Financial Group reissued a “buy” rating and set a GBX 2,500 target price on shares of GSK in a research report on Thursday, May 28th. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a report on Thursday, March 26th. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Citigroup cut their target price on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 1,900 target price on shares of GSK in a research report on Monday, June 8th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of GBX 2,034.29.

View Our Latest Analysis on GSK

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

Featured Stories

• Five stocks we like better than GSK
• Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock
• The Biotech Sector Looks Ready for a Multi-Year Breakout—Here’s What to Watch.
• How Intel Is Packaging the Future of American Chips
• These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.